Abstract
Introduction: Age Related Macular Degeneration (AMD) is a progressive disorder of the macular area that becomes clinically apparent usually after 50 years of age. When it progresses to advanced stages it can result in severe loss of central vision with significant impact on quality of life. Age-related macular degeneration is the leading cause of irreversible blindness in the western world. With the shifting of population distribution to older age groups, the prevalence, effect, and healthcare cost of AMD is expected to increase substantially
Purpose: To measure and contrast biomarkers (high-sensitivity C-reactive protein (hsCRP) and homocysteine (Hcy)) in individuals with age-related macular degeneration (AMD) and control individuals without AMD
Design: Case–control study
Participants: 30 AMD Cases and 30 Healthy Subjects who attended Eye department of Tertiary hospital.
Methods: Both affected and unaffected individuals underwent testing for hsCRP and homocysteine.
Main Outcome Measures: Mean hsCRP and homocysteine levels in affected and unaffected individuals.
Results: Mean hsCRP levels for affected and unaffected individuals were 7.107 and 2.10 mol/l, respectively (P value < 0.01; CI 95%).Mean homocysteine levels for affected and unaffected individuals were 15.89 and 9.67 mol/l, respectively (P value < 0.01; CI 95%). In logistic regression models, elevated hsCRP, and homocysteine were risk factors for AMD. There were no significant differences between cases and controls in terms of Age, gender, Diabetes and Hypertenson.
Conclusion: Elevated levels of hsC-reactive protein and Homocysteine levels are associated with an increased risk of age-related macular degeneration
Keywords: ARM, Homocysteine, hsCRP, Inflammation.
References
- Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933– 43
- Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1992;110:1701– 8.
- Hyman L, Schachat AP, He Q, et al. Hypertension, cardiovascular disease, and age-related macular degeneration. ArchOphthalmol 2000;18:351– 8.
- Seddon JM, Cote J, Davis N, Rosner B. Progression of agerelated macular degene-ration: association with body massindex, wrist circumference, and waist-hip ratio. Arch Ophthalmol 2003;121:785–92.
- Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogenlevels, other cardiovascular risk factors, and age-relatedmaculopathy: the Blue Mountain Eye Study. Arch Ophthalmol1998; 116:583–7.
- Machalińska A, Kawa MP, Marlicz W, Machaliński B. Complement system activationand endothelial dysfunction in patients with age-related macular degeneration(AMD): possible relationship between AMD and atherosclerosis. ActaOphthalmol.2012 Dec;90(8):695-703. doi: 10.1111/j.1755-3768.2011.02295.x. Review. PubMedPMID: 22067048.
- Vingerling JR, Dielemans I, Bots ML, et al. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol 1995;142:404 –9.
- Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775– 81.
- Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135– 43.
- Albert MA, Danielson E, Rifai N, et al. Effect of statintherapyon C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohortstudy. JAMA 2001;286:64 –70.
- Mirhafez SR, Ebrahimi M, Saberi Karimian M, Avan A, Tayefi M, Heidari-Bakavoli A, Parizadeh MR, Moohebati M, Azarpazhooh MR, Esmaily H, Nematy M, SafarianM,Ferns GA, Ghayour-Mobarhan M. Serum high-sensitivity C-reactive protein as abiomarker in patients with metabolic syndrome: evidence-based study with 7284subjects. Eur J ClinNutr. 2016 Nov;70(11):1298-1304. doi: 10.1038/ejcn.2016.111.PubMed PMID: 27460263.
- Mangoni AA, Jackson SH. Homocysteine and cardiovascular disease: current evidence and future prosects. Am J Med2002;112:556 – 65
- Fisher DE, Klein BE, Wong TY, Rotter JI, Li X, Shrager S, Burke GL, Klein R,Cotch MF. Incidence of Age-Related Macular Degeneration in a Multi-Ethnic United States Population: The Multi-Ethnic Study of Atherosclerosis. Ophthalmology.2016 Jun;123(6):1297-308.doi: 0.1016/j.ophtha.2015.12.026. PubMed PMID: 26896123;PubMed Central PMCID: PMC4877264.
- Ridker PM, Hennekens CH, Burning JE, Rifai N. C-reactiveprotein and other markers of inflammation in prediction ofcardiovascular disease in women. N Engl J Med 2000;342:836 – 43.
- Flattem NL, Marx JL, Gawoski J. Fluorescein interference with homocysteine testing. Arch Ophthalmol 2005;123:114–6
- Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. ClinChem1999; 45:2136 – 41.
17. Kizilarslanoğlu MC, Kara Ö, Yeşil Y, Kuyumcu ME, Öztürk ZA, Cankurtaran M, Rahatli S, Pakaştiçali N, Çinar E, Halil MG, Sener B, Cankurtaran ES, Arioğul S. Alzheimer disease, inflammation, and novel inflammatory marker: resistin. Turk J Med Sci. 2015;45(5):1040-6. PubMed PMID: 26738345.
- Anderson DH, Mullins RF, Hageman GS, Johnson LV. A rolefor local inflammation in the formation of drusenin the ageingeye. Am J Ophthalmol 2002;134:411–31.
- Cousins SW, Espinosa-Heidmann DG, Csaky KG. Monocyteactivation in patients with age-related macular degeneration: abiomarker of risk of choroidal neovascularization? Arch Ophthalmol 2004;122:1013– 8.
- Wilson HL, Schwartz DM, Bhatt HR, et al. Statin and aspirintherapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004;137:615–24.
- Albert MA, Danielson E, Rifai N, et al. Effect ofstatintherapyon C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohortstudy. JAMA 2001;286:64 –70.
- Heuberger RA, Fisher AI, Jacques PF, et al. Relation ofblood homocysteine and its nutritional determinants to age related maculopathy in the third National Health and Nutrition Examination Survey. Am J ClinNutr 2002;76:897–902.
- Axer-Siegel R, Bourla D, Ehrlich R, et al. Association ofneovascular age-related macular degeneration and hyperhomocys-teinemia. Am J Ophthalmol 2004;137:84–9.
- Klein R, Klein BE, Marino EK, et al. Early age-related maculopathy in the Cardiovascular Health Study. Ophthalmology 2003;110:25–33.
- Seddon JM, Gensler G, Milton RC, et al. Association betweenC-reactive protein and age-related macular degeneration.JAMA 2004;291:704 –10.
- Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA2003;290:932– 40.
- McCarty CA, Mukesh BN, Guymer RH, et al. Cholesterol lowering medications reduce the risk of age-related maculopathy progression [letter]. Med J Aust 2001;175:340.
- Hall NF, Gale CR, Syddall H, et al. Risk of macular degeneration in users of statins: cross sectional study. BMJ 2001;323:375– 6.
- van Leeuwen R, Vingerling JR, Hofman A, et al. Cholesterol lowering drugs and risk of age-related maculopathy: prospective cohort study with cumulative exposure measurement.BMJ 2003;326: 255– 6.
- Klein R, Klein BE, Tomany SC, et al. Relation of statin use tothe 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol 2003;121:1151–5.
- Klein R, Klein BE. Do statins prevent age-related maculardegeneration? Am J Ophthalmol 2004;137:747–9.
- Manson JE, Gaziano JM, Spelsberg A, et al. A secondaryprevention trial of antioxidant vitamins and cardiovascular disease in women: rationale, design, and methods. Ann Epidemiol 1995;5:261–9.
- VITATOPS Trial Study Group. The VITATOPS (Vitamins toPrevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischemic attack or stroke. Cerebrovasc Dis 2002;13:120 – 6.
Corresponding Author
Dr Shweta Walia
Flat 117, A3, Milan Heights, Near Agarwal Public School, Indore, 452013
Email: This email address is being protected from spambots. You need JavaScript enabled to view it., 9893553234
DOI: https://dx.doi.org/10.18535/jmscr/v6i3.170
